PE20211646A1 - Administracion sostenida de polipeptidos similares a la angiopoyetina 3 - Google Patents
Administracion sostenida de polipeptidos similares a la angiopoyetina 3Info
- Publication number
- PE20211646A1 PE20211646A1 PE2021000422A PE2021000422A PE20211646A1 PE 20211646 A1 PE20211646 A1 PE 20211646A1 PE 2021000422 A PE2021000422 A PE 2021000422A PE 2021000422 A PE2021000422 A PE 2021000422A PE 20211646 A1 PE20211646 A1 PE 20211646A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- angiopoyetin
- similar polypeptides
- sustained administration
- refers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta referido a sistemas de administracion de farmacos que comprende D-R, representado por la Formula I, en donde: D comprende un polipeptido ANGPTL3 que comprende al menos una amina primaria; y R es un enlazador adecuado para la liberacion de D: donde la linea de puntos indica union con la amina primaria; R1 es hidrogeno o alquilo; R1a es H, alquilo, CR1R1a; R2 es alquilo, oxo; a es 0, 1, 2, 3, 4; R3 es H, alquilo; R3a es H, alquilo, CR3R3a; Y es C(O)R4, C(O)OR4, C(O)NHR4, C(O)NR5 R6, SiR5 R6 R7, CR12R12aOR13; Z es CH-L-A, CH-A, N-L-A, o N-A. Tambien esta referido al uso de estos sistemas de administracion de farmacos como terapeutica de liberacion sostenida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862740609P | 2018-10-03 | 2018-10-03 | |
PCT/IB2019/058400 WO2020070675A1 (en) | 2018-10-03 | 2019-10-02 | Sustained delivery of angiopoetin-like 3 polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211646A1 true PE20211646A1 (es) | 2021-08-24 |
Family
ID=68165677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021000422A PE20211646A1 (es) | 2018-10-03 | 2019-10-02 | Administracion sostenida de polipeptidos similares a la angiopoyetina 3 |
Country Status (25)
Country | Link |
---|---|
US (2) | US11389541B2 (es) |
EP (1) | EP3860657A1 (es) |
JP (2) | JP7336513B2 (es) |
KR (1) | KR20210066860A (es) |
CN (1) | CN112770782A (es) |
AR (1) | AR116566A1 (es) |
AU (1) | AU2019353174A1 (es) |
BR (1) | BR112021005981A2 (es) |
CA (1) | CA3112251A1 (es) |
CL (1) | CL2021000819A1 (es) |
CO (1) | CO2021004012A2 (es) |
CR (1) | CR20210156A (es) |
CU (1) | CU20210022A7 (es) |
DO (1) | DOP2021000053A (es) |
EA (1) | EA202190650A1 (es) |
EC (1) | ECSP21022120A (es) |
IL (1) | IL281227A (es) |
JO (1) | JOP20210061A1 (es) |
MX (1) | MX2021003839A (es) |
PE (1) | PE20211646A1 (es) |
PH (1) | PH12021550675A1 (es) |
SG (1) | SG11202102076TA (es) |
TW (1) | TW202027794A (es) |
WO (1) | WO2020070675A1 (es) |
ZA (1) | ZA202101419B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020227364A1 (en) * | 2019-05-07 | 2020-11-12 | Genzyme Corporation | Methods for quantifying drug concentration in a prodrug composition |
CN112220963B (zh) * | 2020-09-24 | 2022-05-24 | 哈尔滨工业大学 | 一种非溶胀uv交联壳聚糖可注射水凝胶及其合成方法 |
TW202306970A (zh) | 2021-05-24 | 2023-02-16 | 瑞士商諾華公司 | 用於治療骨關節炎之方法 |
CN117355323A (zh) | 2021-05-24 | 2024-01-05 | 诺华股份有限公司 | 用于治疗骨关节炎的方法 |
WO2024044608A1 (en) * | 2022-08-23 | 2024-02-29 | Astellas Institute For Regenerative Medicine | Cell cryopreservative formulations and methods of use |
CN117379362A (zh) * | 2023-10-11 | 2024-01-12 | 首都医科大学附属北京潞河医院 | 负载血管生成素样蛋白3的水凝胶及其制备方法与应用 |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
DE3737523A1 (de) | 1987-11-05 | 1989-05-18 | Bayer Ag | Verwendung von substituierten hydroxypiperidinen als antivirale mittel |
US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
US5288931A (en) | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
EP0712635B1 (en) | 1994-05-13 | 2003-05-02 | Kuraray Co., Ltd. | Medical polymer gel |
WO1998009987A1 (en) | 1996-09-06 | 1998-03-12 | Biochem Pharma, Inc. | Lactam inhibitors of thrombin |
US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
AU3661199A (en) | 1998-04-27 | 1999-11-16 | Zymogenetics Inc. | Novel polypeptide growth factors and materials and methods for making them |
CA2332109A1 (en) | 1998-05-12 | 1999-11-18 | Human Genome Sciences, Inc. | 97 human secreted proteins |
AU4643699A (en) | 1998-06-24 | 2000-01-10 | Compugen Ltd. | Angiopoietin-like growth factor sequences |
EP1374908A3 (en) | 1998-10-09 | 2004-03-24 | The Regents Of The University Of Michigan | Polymer-drug conjugates comprising hydrazide linkers |
JP2003531811A (ja) | 1999-03-08 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 血管形成及び心臓血管新生の促進又は阻害 |
GB9912350D0 (en) | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
ES2291198T3 (es) | 1999-07-20 | 2008-03-01 | Genentech, Inc. | Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico. |
US20030013649A1 (en) | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
ES2304401T3 (es) | 2000-10-16 | 2008-10-16 | Genentech, Inc. | Metodos de tratamiento que utilizan polipeptidos wisp. |
US20040249141A1 (en) | 2000-10-16 | 2004-12-09 | Audrey Goddard | Tie ligand homologues |
JP2004524297A (ja) | 2001-01-23 | 2004-08-12 | イーライ・リリー・アンド・カンパニー | メラノコルチン受容体アゴニスト |
US20030027751A1 (en) | 2001-04-10 | 2003-02-06 | Genvec, Inc. | VEGF fusion proteins |
US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
FI117667B (fi) | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
MXPA04004609A (es) | 2001-11-16 | 2004-08-12 | Genentech Inc | Composicion que comprende y metodo para utilizar angptl3 de proteina 3 como angiopoyetina. |
JP4764630B2 (ja) | 2002-09-09 | 2011-09-07 | ネクター セラピューティックス | 水溶性ポリマーアルカナール |
EP1664091A1 (en) | 2003-09-18 | 2006-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
CA2786794C (en) | 2004-03-23 | 2017-09-12 | Complex Biosystems Gmbh | Aromatic polymeric cascade prodrug linker reagent |
US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
JP2008532516A (ja) | 2005-03-11 | 2008-08-21 | ジェネンテック・インコーポレーテッド | 遺伝子破壊、組成物、およびそれに関連する方法 |
US7807464B2 (en) | 2005-05-24 | 2010-10-05 | Whitehead Institute For Biomedical Research | Methods for expansion and analysis of cultured hematopoietic stem cells |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
WO2007003054A1 (en) | 2005-07-06 | 2007-01-11 | Shoichet Molly S | Method of biomolecule immobilization on polymers using click-type chemistry |
US20070060658A1 (en) | 2005-08-31 | 2007-03-15 | Diaz David D | Stabilization of organogels and hydrogels by azide-alkyne [3+2] cycloaddition |
ITMI20061726A1 (it) | 2006-09-11 | 2008-03-12 | Fidia Farmaceutici | Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry |
KR101460815B1 (ko) | 2006-12-06 | 2014-11-12 | 세이가가쿠 고교 가부시키가이샤 | 관절염 질환 치료의 지속성 효과를 갖는 제약 제제 |
CA2672049C (en) | 2006-12-08 | 2016-05-10 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angptl3 |
CN101600428A (zh) | 2007-02-09 | 2009-12-09 | Irm责任有限公司 | 作为通道活化蛋白酶抑制剂的化合物和组合物 |
US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
AR065860A1 (es) | 2007-03-29 | 2009-07-08 | Novartis Ag | 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas |
EP2155862A2 (en) | 2007-05-04 | 2010-02-24 | Whitehead Institute For Biomedical Research | Ex vivo expansion of human hematopoietic stem cells |
AU2008258548B2 (en) | 2007-06-08 | 2014-07-10 | Sanofi-Aventis Deutschland Gmbh | Long-acting transient polymer conjugates of exendin |
WO2009095954A2 (ja) | 2008-01-31 | 2009-08-06 | Appside Co., Ltd. | データ入力装置、データ入力方法ならびにデータ入力プログラムおよびこれを記録した記録媒体 |
EP2596805B1 (en) | 2008-02-01 | 2021-10-27 | Ascendis Pharma A/S | Prodrug comprising a drug-linker conjugate |
US20110230497A1 (en) | 2008-11-07 | 2011-09-22 | H. Lundbeck A/S | Biologically active amides |
US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
US8648144B2 (en) | 2009-02-21 | 2014-02-11 | Sofradim Production | Crosslinked fibers and method of making same by extrusion |
WO2010099818A1 (en) | 2009-03-03 | 2010-09-10 | Ao Technology Ag | Thermoreversible polysaccharide hydrogel |
WO2010102663A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Piperazine derivatives for use in therapy |
IN2012DN00352A (es) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
TW201113280A (en) | 2009-07-03 | 2011-04-16 | Nensius Res As | Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the CNS |
CA2767826C (en) | 2009-07-14 | 2015-11-24 | The Scripps Research Institute | Mesenchymal stem cell differentiation using aniopoietin-like-3 |
EP2459225A1 (en) | 2009-07-31 | 2012-06-06 | Ascendis Pharma A/S | Carrier linked pramipexole prodrugs |
RU2556340C2 (ru) | 2009-07-31 | 2015-07-10 | Санофи-Авентис Дойчланд Гмбх | Композиция инсулина длительного действия |
BR112012002280B1 (pt) | 2009-07-31 | 2020-04-07 | Ascendis Pharma As | hidrogel insolúvel em água baseado em polietileno glicol biodegradável, seu processo de preparação, conjugado, composto ligado a veículo e composição farmacêutica. |
PE20120918A1 (es) | 2009-07-31 | 2012-08-14 | Sanofi Aventis Deutschland | Profarmacos que comprenden un conjugado de insulina-conector |
EP2459227B1 (en) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
WO2011012723A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Injectable sustained release compositions comprising a pramipexole prodrug |
EP2485712A1 (en) | 2009-10-06 | 2012-08-15 | Ascendis Pharma A/S | Subcutaneous paliperidone composition |
EP2485767A1 (en) | 2009-10-06 | 2012-08-15 | Ascendis Pharma A/S | Carrier linked paliperidone prodrugs |
MX2012004499A (es) | 2009-10-29 | 2012-05-29 | Ascendis Pharma As | Esterilizacion de hidrogeles biodegradables. |
WO2011089215A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
WO2011089216A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
US9561285B2 (en) | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
EP2563753B9 (en) | 2010-04-27 | 2016-07-06 | SynAffix B.V. | Fused cyclooctyne compounds and their use in metal-free click reactions |
CN103025164B (zh) | 2010-05-05 | 2017-03-08 | 普罗林科斯有限责任公司 | 从固体支撑物中药物的控制释放 |
AU2011283684B2 (en) | 2010-07-29 | 2015-08-27 | Rigel Pharmaceuticals, Inc. | AMPK-activating heterocyclic compounds and methods for using the same |
CN103492562B (zh) | 2011-02-03 | 2017-04-05 | 佐马技术有限公司 | 用于增强细菌中功能蛋白表达的方法和材料 |
US9388276B2 (en) | 2011-02-25 | 2016-07-12 | University Of Massachusetts | Monomers and polymers for functional polycarbonates and poly(ester-carbonates) and PEG-co-polycarbonate hydrogels |
US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
CZ304072B6 (cs) | 2011-04-26 | 2013-09-25 | Contipro Biotech S.R.O. | Amfoterní materiál na bázi sítované kyseliny hyaluronové, zpusob jeho prípravy, materiály obsahující aktivní cinidla uzavrené v síti hyaluronanu, zpusob jejich prípravy a jejich pouzití |
JPWO2012165462A1 (ja) | 2011-05-31 | 2015-02-23 | 国立大学法人 東京大学 | ハイドロゲル及びその製造方法 |
WO2012173952A1 (en) | 2011-06-13 | 2012-12-20 | Emory University | Piperazine derivatives, compositions, and uses related thereto |
KR20140082649A (ko) | 2011-08-12 | 2014-07-02 | 아센디스 파마 에이에스 | 프로스타사이클린의 서방형 조성물 |
JP6158185B2 (ja) | 2011-09-07 | 2017-07-05 | プロリンクス エルエルシー | 生分解性架橋を有するヒドロゲル |
US20130066063A1 (en) | 2011-09-09 | 2013-03-14 | John Cooke Hodges | Bicyclo[6.1.0]non-4-yne regents for chemical modification of oligonucleotides |
RU2014118642A (ru) | 2011-10-12 | 2015-11-20 | Асцендис Фарма Офтальмолоджи Дивижн А/С | Предотвращение и лечение глазных нарушений |
CN104136606A (zh) | 2011-12-01 | 2014-11-05 | 安吉奥开米公司 | 靶向的艾杜糖-2-硫酸酯酶化合物 |
JP2013116858A (ja) | 2011-12-01 | 2013-06-13 | Dainippon Sumitomo Pharma Co Ltd | Bdnf様低分子化合物を含有する治療薬 |
WO2013078564A2 (en) | 2011-12-01 | 2013-06-06 | Angiochem Inc. | Targeted lysosomal enzyme compounds |
WO2013171485A1 (en) | 2012-05-18 | 2013-11-21 | Medical Research Council | Methods of incorporating an amino acid comprising a bcn group into a polypeptide using an orthogonal codon encoding it and an orthorgonal pylrs synthase. |
EP3369747A1 (en) | 2012-06-25 | 2018-09-05 | The Brigham and Women's Hospital, Inc. | Targeted theratpeutics |
AU2013328785B2 (en) | 2012-10-11 | 2016-07-21 | Ascendis Pharma A/S | Hydrogel prodrugs |
US10980860B2 (en) | 2012-10-11 | 2021-04-20 | Ascendis Pharma A/S | Diagnosis, prevention and treatment of diseases of the joint |
SG11201501914XA (en) | 2012-10-11 | 2015-05-28 | Ascendis Pharma Ophthalmology Division As | Vegf neutralizing prodrugs for the treatment of ocular conditions |
WO2014059446A1 (en) | 2012-10-12 | 2014-04-17 | Case Western Reserve University | Biodegradable hydrogel for polynucleotide delivery |
US20150352246A1 (en) | 2013-01-22 | 2015-12-10 | Prolynx Llc | Sealants having controlled degration |
US9301971B2 (en) | 2013-03-08 | 2016-04-05 | Novartis Ag | Peptides and compositions for treatment of joint damage |
JO3564B1 (ar) | 2013-03-08 | 2020-07-05 | Novartis Ag | ببتيدات وتركيبات لعلاج ضرر المفاصل |
MA38396B1 (fr) | 2013-03-15 | 2019-05-31 | Novartis Ag | Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit |
US20160089446A1 (en) | 2013-04-22 | 2016-03-31 | Ascendis Pharma A/S | Modified Hydrogels |
EP2988783A1 (en) | 2013-04-22 | 2016-03-02 | Ascendis Pharma A/S | Hydrogel-linked prodrugs releasing modified drugs |
WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
CN104292454B (zh) | 2013-07-17 | 2017-12-01 | 北京键凯科技股份有限公司 | 聚乙二醇‑环辛炔衍生物 |
JP2016172783A (ja) | 2013-08-08 | 2016-09-29 | 生化学工業株式会社 | 組織膨隆材 |
US20180042996A1 (en) | 2013-10-08 | 2018-02-15 | Ascendis Pharma Osteoarthritis Division A/S | Hydrogel-Linked IL-1ra Prodrug |
KR20160075665A (ko) | 2013-10-22 | 2016-06-29 | 프로린크스 엘엘시 | 소마토스타틴 및 그 유사체의 컨쥬게이트 |
WO2015067791A1 (en) | 2013-11-11 | 2015-05-14 | Ascendis Pharma Relaxin Division A/S | Relaxin prodrugs |
CA2940550C (en) | 2014-02-26 | 2023-01-17 | University Of Massachusetts | Degradable hydrogel with predictable tuning of properties, and compositions and methods thereof |
EP3193941A1 (en) | 2014-08-06 | 2017-07-26 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
WO2016025752A1 (en) | 2014-08-14 | 2016-02-18 | Prolynx Llc | Reagents for thiol conjugation and conjugates formed therefrom |
TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
US20170368189A1 (en) | 2015-01-09 | 2017-12-28 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs |
MA41794A (fr) * | 2015-03-18 | 2018-01-23 | The California Institute For Biomedical Res | Agents thérapeutiques modifiés et compositions associées |
US11298427B2 (en) | 2015-05-29 | 2022-04-12 | Ascendis Pharma A/S | Prodrugs comprising a pyroglutamate linker |
EP3377047A1 (en) | 2015-11-20 | 2018-09-26 | Cristal Delivery B.V. | Nanoparticles with active targeting |
CA3016814A1 (en) | 2016-03-16 | 2017-09-21 | Prolynx Llc | Extended release conjugates of exenatide analogs |
WO2018011266A1 (en) | 2016-07-13 | 2018-01-18 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
-
2019
- 2019-10-01 AR ARP190102781A patent/AR116566A1/es unknown
- 2019-10-01 TW TW108135606A patent/TW202027794A/zh unknown
- 2019-10-02 KR KR1020217012201A patent/KR20210066860A/ko not_active Application Discontinuation
- 2019-10-02 EP EP19783723.0A patent/EP3860657A1/en active Pending
- 2019-10-02 AU AU2019353174A patent/AU2019353174A1/en active Pending
- 2019-10-02 US US16/591,053 patent/US11389541B2/en active Active
- 2019-10-02 CU CU2021000022A patent/CU20210022A7/es unknown
- 2019-10-02 JO JOP/2021/0061A patent/JOP20210061A1/ar unknown
- 2019-10-02 CA CA3112251A patent/CA3112251A1/en active Pending
- 2019-10-02 SG SG11202102076TA patent/SG11202102076TA/en unknown
- 2019-10-02 MX MX2021003839A patent/MX2021003839A/es unknown
- 2019-10-02 JP JP2021517752A patent/JP7336513B2/ja active Active
- 2019-10-02 CR CR20210156A patent/CR20210156A/es unknown
- 2019-10-02 BR BR112021005981-4A patent/BR112021005981A2/pt unknown
- 2019-10-02 CN CN201980064248.5A patent/CN112770782A/zh active Pending
- 2019-10-02 WO PCT/IB2019/058400 patent/WO2020070675A1/en active Application Filing
- 2019-10-02 PE PE2021000422A patent/PE20211646A1/es unknown
- 2019-10-02 EA EA202190650A patent/EA202190650A1/ru unknown
-
2021
- 2021-03-02 ZA ZA2021/01419A patent/ZA202101419B/en unknown
- 2021-03-03 IL IL281227A patent/IL281227A/en unknown
- 2021-03-25 PH PH12021550675A patent/PH12021550675A1/en unknown
- 2021-03-30 EC ECSENADI202122120A patent/ECSP21022120A/es unknown
- 2021-03-30 DO DO2021000053A patent/DOP2021000053A/es unknown
- 2021-03-30 CO CONC2021/0004012A patent/CO2021004012A2/es unknown
- 2021-03-31 CL CL2021000819A patent/CL2021000819A1/es unknown
-
2022
- 2022-05-26 US US17/804,217 patent/US20220323595A1/en not_active Abandoned
-
2023
- 2023-07-06 JP JP2023111526A patent/JP2023145478A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2021003839A (es) | 2021-05-27 |
CU20210022A7 (es) | 2021-10-12 |
US20200108153A1 (en) | 2020-04-09 |
TW202027794A (zh) | 2020-08-01 |
JP2023145478A (ja) | 2023-10-11 |
DOP2021000053A (es) | 2021-04-30 |
US20220323595A1 (en) | 2022-10-13 |
JP7336513B2 (ja) | 2023-08-31 |
CN112770782A (zh) | 2021-05-07 |
AR116566A1 (es) | 2021-05-19 |
CA3112251A1 (en) | 2020-04-09 |
BR112021005981A2 (pt) | 2021-06-29 |
WO2020070675A1 (en) | 2020-04-09 |
KR20210066860A (ko) | 2021-06-07 |
CR20210156A (es) | 2021-04-28 |
CL2021000819A1 (es) | 2021-11-12 |
EP3860657A1 (en) | 2021-08-11 |
CO2021004012A2 (es) | 2021-04-19 |
PH12021550675A1 (en) | 2022-01-03 |
ECSP21022120A (es) | 2021-04-29 |
ZA202101419B (en) | 2022-07-27 |
IL281227A (en) | 2021-04-29 |
SG11202102076TA (en) | 2021-04-29 |
AU2019353174A1 (en) | 2021-04-01 |
JOP20210061A1 (ar) | 2023-01-30 |
US11389541B2 (en) | 2022-07-19 |
EA202190650A1 (ru) | 2021-07-21 |
JP2022501406A (ja) | 2022-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211646A1 (es) | Administracion sostenida de polipeptidos similares a la angiopoyetina 3 | |
PE20211281A1 (es) | Sistemas de administracion de liberacion sostenida que comprenden ligantes que no dejan huellas | |
CL2022001625A1 (es) | Derivados de pirazolilo útiles como agentes anti-cancerígenos | |
CL2019001466A1 (es) | Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico. | |
DOP2022000091A (es) | Degradadores de moléculas pequeñas de helios y procedimientos de uso | |
ECSP22071009A (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
CO7111284A2 (es) | Nucleósidos de espirooxetano de uracilo | |
UY30736A1 (es) | Compuestos quimicos 537 | |
CR10842A (es) | Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico por imagenes | |
CL2020001020A1 (es) | Derivados de bencimidazol y sus usos. | |
CL2019001991A1 (es) | Moduladores del receptor de estrógeno. | |
ECSP19019613A (es) | Compuestos de azaindazol para usar en lesiones de tendones y/o ligamentos | |
CR20160084A (es) | Derivados de amida como agonistas del receptor del ácido lisofosfatídico | |
CY1124301T1 (el) | Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων | |
ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 | |
PE20211280A1 (es) | Sales cristalinas de un inhibidor de calicreina plasmatica | |
CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
BR112016023991A2 (pt) | ativadores de herg policíclicos | |
CL2022002622A1 (es) | Uso terapéutico de agonista trigonal de los receptores de glucagon, glp-1 y gip o conjugado (divisional solicitud 202103499) | |
CL2022002490A1 (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead |